Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Published:2021-06 Issue:6 Volume:8 Page:e410-e421
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Straus David J,Długosz-Danecka Monika,Connors Joseph M,Alekseev Sergey,Illés Árpád,Picardi Marco,Lech-Maranda Ewa,Feldman Tatyana,Smolewski Piotr,Savage Kerry J,Bartlett Nancy L,Walewski Jan,Ramchandren Radhakrishnan,Zinzani Pier Luigi,Hutchings Martin,Munoz Javier,Lee Hun Ju,Kim Won Seog,Advani Ranjana,Ansell Stephen M,Younes Anas,Gallamini Andrea,Liu Rachael,Little Meredith,Fenton Keenan,Fanale Michelle,Radford John

Funder

Seagen Inc

Publisher

Elsevier BV

Subject

Hematology

Reference28 articles.

1. Hodgkin lymphoma, version 2.2020, NCCN Clinical Practice Guidelines in Oncology;Hoppe;J Natl Compr Canc Netw,2020

2. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD;Canellos;N Engl J Med,1992

3. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group;Behringer;J Clin Oncol,2005

4. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials;Andre;Cancer Med,2020

5. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma;Stephens;Blood,2019

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma;JCO Oncology Practice;2024-09-12

2. At the Cutting Edge: Novel Agents in Hodgkin Lymphoma and the Evolving Role of Radiation Therapy;International Journal of Radiation Oncology*Biology*Physics;2024-09

3. Management of Peripheral Neuropathy Associated with Brentuximab Vedotin in the Frontline Treatment of Classical Hodgkin Lymphoma;Critical Reviews in Oncology/Hematology;2024-09

4. Management of Neurotoxic Reactions Induced by Antibody-Drug Conjugates;Asia-Pacific Journal of Oncology Nursing;2024-09

5. Monoclonal Antibody Therapies in Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28